* The findings from TTrials, TRAVERSE, T4DM and other recent studies have provided high-quality evidence of the metabolic benefits and low risk of serious adverse events associated with testosterone therapy. Reflecting this new evidence, the FDA revised its black box warning regarding testosterone and cardiovascular risks in 2025.
* Testosterone treatment can also produce erythrocytosis; however, the incidence of erythrocytosis with physiological doses of testosterone replacement was low and not associated with cardiovascular events in...
ExcelMale Newsletter Signup
Stay Informed with Our Newsletter
Get the latest men's health insights, expert advice, and community updates delivered to your inbox.